NewSquare Capital LLC Purchases 156 Shares of Cencora, Inc. $COR

NewSquare Capital LLC raised its position in Cencora, Inc. (NYSE:COR) by 202.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 233 shares of the company’s stock after purchasing an additional 156 shares during the period. NewSquare Capital LLC’s holdings in Cencora were worth $70,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of COR. Atlantic Edge Private Wealth Management LLC lifted its position in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Cornerstone Planning Group LLC lifted its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after acquiring an additional 48 shares during the last quarter. Costello Asset Management INC bought a new stake in Cencora in the first quarter valued at approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora during the 1st quarter valued at $39,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Cencora during the second quarter valued at about $61,000. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

NYSE COR opened at $352.83 on Thursday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $361.38. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The company has a market capitalization of $68.41 billion, a PE ratio of 36.30, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The business’s fifty day moving average is $311.49 and its 200 day moving average is $298.36.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the previous year, the firm earned $3.34 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 22.63%.

Analyst Ratings Changes

COR has been the subject of a number of recent analyst reports. Evercore ISI set a $340.00 target price on Cencora in a report on Wednesday, October 8th. Wells Fargo & Company upped their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Mizuho increased their price objective on shares of Cencora from $334.00 to $340.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Finally, Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $329.55.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 41,544 shares of company stock worth $12,230,941 in the last three months. Insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.